TABLE 4.
Drug | Patient group | Specificity (%) | Sensitivity (%) | NPV (%) | PPV (%) | Efficiency |
---|---|---|---|---|---|---|
INHL | New | 97.3 | 92.3 | 98.9 | 82.8 | 0.967 |
Previously treated | 90.0 | 96.3 | 90.0 | 96.3 | 0.946 | |
Combined | 96.9 | 94.3 | 98.4 | 89.3 | 0.964 | |
INHH | New | 99.5 | 95.7 | 99.5 | 95.7 | 0.990 |
Previously treated | 83.3 | 84.0 | 71.4 | 91.3 | 0.838 | |
Combined | 98.5 | 89.6 | 97.5 | 93.5 | 0.967 | |
RIF | New | 100.0 | 100.0 | 100.0 | 100.0 | 1.000 |
Previously treated | 94.7 | 89.5 | 89.5 | 94.4 | 0.919 | |
Combined | 99.5 | 92.3 | 99.1 | 96 | 0.988 | |
MDR | New | 100.0 | 100.0 | 100.0 | 100.0 | 1.000 |
Previously treated | 94.4 | 89.5 | 89.5 | 94.4 | 0.919 | |
Combined | 99.5 | 92 | 99.1 | 95.8 | 0.988 |